search button

Binding affinities of paclitaxel and docetaxel for generic and nanoparticle albumin‑bound paclitaxel‑derived albumin from human serum

  • Authors:
    • Takamichi Sato
    • Manami Okazaki
    • Junko Sano
    • Chihiro Kato
    • Kazuhisa Shimizu
    • Masayuki Kitagawa

  • View Affiliations

  • Published online on: February 11, 2021     https://doi.org/10.3892/br.2021.1411
  • Article Number: 35
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Nanoparticle albumin‑bound (nab)‑paclitaxel is a 130‑nm formulation containing human serum albumin (HSA). The clinical efficacy of this formulation is considered to depend on its affinity for HSA. The high pressure employed during the manufacture of nab‑paclitaxel HSA (nab HSA) may influence its conformation and/or oligomerization, and ultimately its affinity for HSA. Therefore, studies are required to evaluate whether the affinity of paclitaxel for nab HSA is similar to that of generic HSA (control HSA). In the present study, nab HSA was isolated from nab‑paclitaxel by gel filtration, and the binding affinities (KDs) were determined by surface plasmon resonance. Furthermore, the affinity of docetaxel for nab HSA and control HSA was measured, as their binding sites are similar. Paclitaxel showed KDs of 8.93±8.60 and 7.39±5.81 µM for nab HSA and control HSA, respectively, whereas the corresponding KDs for docetaxel were 44.3±9.50 and 55.9±2.28 µM, respectively. This suggests that the paclitaxel binding site was not modified during the nab‑paclitaxel manufacturing process. Additionally, nab HSA likely does not affect paclitaxel and blood HSA binding, as evidenced by the similar affinities of paclitaxel and docetaxel for nab HSA and control HSA. In conclusion, the binding affinities of paclitaxel and docetaxel for nab HSA and control HSA were found to be comparable. Additionally, the manufacturing process did not influence the paclitaxel binding affinity for nab HSA. These results also suggest that nab HSA may not affect the clinical effectiveness of nab‑paclitaxel.
View Figures
View References

Related Articles

Journal Cover

April-2021
Volume 14 Issue 4

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.3
  • Ranked
    (total number of cites)
  • CiteScore: 4.1
  • CiteScore Rank: Q1: #19/80 Pharmacology, Toxicology and Pharmaceutics
  • Source Normalized Impact per Paper (SNIP): 0.7
  • SCImago Journal Rank (SJR): 0.514
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Sato T, Okazaki M, Sano J, Kato C, Shimizu K and Kitagawa M: Binding affinities of paclitaxel and docetaxel for generic and nanoparticle albumin‑bound paclitaxel‑derived albumin from human serum. Biomed Rep 14: 35, 2021.
APA
Sato, T., Okazaki, M., Sano, J., Kato, C., Shimizu, K., & Kitagawa, M. (2021). Binding affinities of paclitaxel and docetaxel for generic and nanoparticle albumin‑bound paclitaxel‑derived albumin from human serum. Biomedical Reports, 14, 35. https://doi.org/10.3892/br.2021.1411
MLA
Sato, T., Okazaki, M., Sano, J., Kato, C., Shimizu, K., Kitagawa, M."Binding affinities of paclitaxel and docetaxel for generic and nanoparticle albumin‑bound paclitaxel‑derived albumin from human serum". Biomedical Reports 14.4 (2021): 35.
Chicago
Sato, T., Okazaki, M., Sano, J., Kato, C., Shimizu, K., Kitagawa, M."Binding affinities of paclitaxel and docetaxel for generic and nanoparticle albumin‑bound paclitaxel‑derived albumin from human serum". Biomedical Reports 14, no. 4 (2021): 35. https://doi.org/10.3892/br.2021.1411